Business
ANGLE announces collaboration with Myriad Genetics
Angle plc announced a collaboration with Myriad Genetics to assess the feasibility of using Parsortix-derived circulating tumor cell (CTC) DNA with Myriad Genetics' existing tissue-based diagnostic tests. The collaboration involves processing blood samples from cancer patients using ANGLE's Parsortix system to capture intact cancer cells for molecular analysis. Results will compare CTC-DNA with matched patient tissue samples using Myriad Genetics' assay. Further details of the agreement are confidential. Angle's CEO, Andrew Newland, stated the collaboration has the potential to substantially impact patient treatment by improving access to actionable genomic data. Disclaimer*
About this update from Cellbxhealth Plc
[{"type":"text","content":"\n\n\n\n\n\nFor immediate release\n\n\n20 August 2025\n\n\n\n\n \nANGLE plc (\"the Company\")\n \nCOLLABORATION WITH MYRIAD GENETICS \n \nAssessment of feasibility for use of Parsortix derived circulating tumour cell (CTC) DNA with Myriad Genetics' existing tissue-based diagnostic test \n \n \nANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, is delighted to announce that it has entered a collaboration with Myriad Genetics, Inc. (MYGN:NSQ), a leading molecular diagnostic testing and precision medicine company dedicated to advancing health and well-being for all.\n \nUnder the terms of the agreement, blood samples from cancer patients will be processed by ANGLE's research and development team utilising the Parsortix® system for the capture and harvest of intact cancer cells for downstream molecular analysis. Results for this analysis will compare CTC-DNA with matched patient tissue samples using Myriad Genetics' existing tissue-based assay.\n \nFurther details of the agreement are confidential between the parties.\n \n \nANGLE Chief Executive, Andrew Newland, commented:\n\"We are delighted to be working with Myriad Genetics, a major player in tissue-based companion diagnostic tests, seeking to extend their tests to work on a simple blood test using CTCs harvested by the Parsortix system. We look forward to working with Myriad Genetics to progress this collaboration which has the potential to have a substantial impact on patient treatment by improving access to actionable genomic data.\"\n \n \n \nFor further information:\n \n\n\n\n\nANGLE plc\n\n\n+44 (0) 1483 343434\n\n\n\n\nAndrew Newland, Chief Executive\nIan Griffiths, Finance Director\n\n\n \n \n\n\n\n\n \nBerenberg (NOMAD and Broker)\nToby Flaux, Ciaran Walsh, Milo Bonser\n\n\n \n+44 (0) 20 3207 7800\n\n\n\n\n \nFTI Consulting\nSimon Conway, Ciara Martin\nMatthew Ventimiglia (US)\n\n\n \n \n+44 (0) 203 727 1000\n+1 (212) 850 5624\n\n\n\n\n \n \nThe information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the EU Market Abuse Regulation (5...